Stability indicating RP-HPLC method development and validation for the simultaneous determination of vilanterol trifinatate and umeclidinium bromide in bulk and pharmaceutical dosage forms

Authors

  • G. Indira Priyadarshini Department of Pharmaceutical Analysis, Hindu College of Pharmacy, Guntur – 522002, Andhra Pradesh, India
  • N. Naga Udayasri Department of Pharmaceutical Analysis, Hindu College of Pharmacy, Guntur – 522002, Andhra Pradesh, India
  • M. Lakshmi Sowmya Department of Pharmaceutical Analysis, Hindu College of Pharmacy, Guntur – 522002, Andhra Pradesh, India
  • Nagaraju Pappula Department of Pharmaceutical Analysis, Hindu College of Pharmacy, Guntur – 522002, Andhra Pradesh, India

Keywords:

Vilanterol trifinatate, Umeclidinium bromide, RP-HPLC

Abstract

A simple, Accurate, precise method was developed for the simultaneous estimation of the Vilanterol trifinatate and Umeclidinium bromide in dosage form. Chromatogram was run through symmetry C18 (150 x 4.6 mm, 5n). Mobile phase containing Water: Acetonitrile taken in the ratio 65:35 was pumped through column at a flow rate of 1.0ml/min. Retention time of Vilanterol trifinatate and Umeclidinium bromide were found to be 2.96 min and 2.315 min. %RSD of the Vilanterol trifinatate and Umeclidinium bromide were and found to be 1.0 and 0.6 respectively. %Recovery was obtained as 101.8% and 99.78% for Vilanterol trifinatate and Umeclidinium bromide respectively. LOD, LOQ values obtained from regression equations of Vilanterol trifinatate and Umeclidinium bromide Vilanterol were 0.54, 0.18 and 0.16, 0.05 respectively. Regression equation of Vilanterol trifinatate is y = 9969.6x +1935.1 and y =9122.6x + 6120.9 of Umeclidinium bromide. Retention times were decreased and that run time was decreased, so the method developed was simple and economical that can be adopted in regular Quality control test in Industries.

Downloads

Published

2021-01-24

How to Cite

G. Indira Priyadarshini, N. Naga Udayasri, M. Lakshmi Sowmya, & Nagaraju Pappula. (2021). Stability indicating RP-HPLC method development and validation for the simultaneous determination of vilanterol trifinatate and umeclidinium bromide in bulk and pharmaceutical dosage forms . World Journal of Pharmaceutical Sciences, 9(2), 137–143. Retrieved from https://wjpsonline.com/index.php/wjps/article/view/92

Issue

Section

Research Article